Escudo Universidad de Antioquia

Sistema de Bibliotecas

Universidad de Antioquia

Biblioteca Digital


Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10495/11578
Título : Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2
Autor : Martínez Gutiérrez, Marlén
Castellanos Parra, Jaime Eduardo
Gallego Gomez, Juan Carlos
Osorio Benitez, Jorge Emilio
Correa Londoño, Luis Alfonso
Palabras clave : Virus del dengue
Dengue
Treatment outcome
Lovastatina
Agente antiviral
Viremia
Virus assembly
Fecha de publicación : 2014
Editorial : Public Library of Science
Citación : Martinez-Gutierrez M, Correa-Londoño LA, Castellanos JE, Gallego-Gómez JC, Osorio JE. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS One. 2014 Feb 21;9(2):e87412
Abstract : Background: It has been reported that treatment of DENV-infected cultures with Lovastatin (LOV), can affect viral assembly. The objective of this study was to evaluate the effect of LOV on the survival rate and viremia levels of DENV-2-infected AG129 mice. Methodology/Principal Findings: Mice were inoculated with 16106 plaque-forming units (PFU/ml) of DENV-2 and treated with LOV (200 mg/kg/day). Pre-treatment with one or three doses of LOV increased the survival rate compared to untreated mice (7.3 and 7.1 days, respectively, compared to 4.8 days). Viremia levels also decreased by 21.8% compared to untreated mice, but only in the group administered three doses prior to inoculation. When LOV was administered after viral inoculation, the survival rate increased (7.3 days in the group treated at 24 hpi, 6.8 days in the group treated at 48 hpi and 6.5 days in the group treated with two doses) compared to the untreated group (4.8 days). Interestingly, the serum viral titer increased by 24.6% in mice treated at 48 hpi with a single dose of LOV and by 21.7% in mice treated with two doses (at 24 and 48 hpi) of LOV compared to untreated mice. Finally histopathological changes in the liver and spleen in infected and untreated mice included massive extramedullary erythropoiesis foci and inflammatory filtration, and these characteristics were decreased or absent in LOV-treated mice. Conclusions/Significance: Our results suggest that the effect of LOV on viremia depends on the timing of treatment and on the number of doses administered. We observed a significant increase in the survival rate in both schemes due to a delay in the progression of the disease. However, the results obtained in the post-treatment scheme must be handled carefully because this treatment scheme increases viremia and we do not know how this increase could affect disease progression in humans.
Grupo de INV. : Programa de Estudio y Control de Enfermedades Tropicales (PECET)
URI : http://hdl.handle.net/10495/11578
ISSN : 19326203
Aparece en las colecciones: Instituto de Investigaciones Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
MartinezGutierrezMarlen_2014_LovastatinInfectionIncreases.pdfMartinezGutierrezMarlen_2014_LovastatinInfectionIncreases13,85 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons

 


Unidad de Gestión Tecnológica /Sistema de Bibliotecas / Universidad de Antioquia / Cl. 67 Nº 53 - 108 - Bloque 8 Conmutador: 219 51 51- 219 51 40 comunicacionessistemadebibliotecas@udea.edu.co Medellín - Colombia